TheraLode

TheraLode magnetically unlocks the full value of thrombolytics so that ten times more stroke patients can be better treated.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded August 2024
  • Employees 7
  • Incorporation Type LLC
  • Website unandup.com

Company Summary

TheraLode is a disruptive magneto-thrombolytic platform for acute ischemic stroke. Because 90% of stroke patients receive no interventional care due to ineffective therapies, hemorrhage, and poor availability, 90% die or are left disabled. By overcoming these barriers, TheraLode can treat 10X more stroke patients and expand the US stroke market to $6B annually. The global opportunity increases to $53B including clots in hearts, lungs, and legs.

Team

  • CEO and President

    I have a PhD in theoretical physics and am an expert in medical magnetics and magnetic nanoparticles with nearly 50 issued patents. I am the Founder/CEO of TheraLode and its parent company, UNandUP, LLC. Previously, I founded Pulse Therapeutics and was a founding design team member at Stereotaxis. I have experience with US and international regulatory approvals, overseen preclinical testing, and managed a human clinical stroke trial in Australia.

  • Peter S. Finley
    COO and Co-Founder

    I like helping smart people who have novel discontinuous solutions which are finding and proving product/market fit. Co-founder of UN&UP (biotech), Observable Networks (cybersecurity), Thompson Street Capital (private equity). Experienced fundraiser with over $1B raised in 2 IPOs, 2 secondary offerings, 2 PE funds, several early VC rounds, multiple bank and private debt placements.

  • David C. Greenspan
    Lead Material Scientist

    Over 40 years of product development and management experience in the medical nanoparticle and device industries, including the development of magnetic nanoparticles, bioactive glass products, orthopedic and dental bone graft materials, nano materials for drug delivery and other applications, and allograft and xenograft products.

  • Director of Product Development

    Ms. Morrell has a decade of experience in medical device start-ups and translating technologies to the marketplace across three continents. She has successfully managed vendors, international, and multidisciplinary teams, and executed rapid-iterative low budget initiatives and formal summative testing for multinational customers. Her contributions have led to four successful 510(k) filings and device launches.

  • Chief Program Officer

    Experienced entrepreneur with a demonstrated history of working in the medical device industry. Strong research professional skilled in Medical Devices, Biotechnology, Biomedical Engineering, Data Analysis, and Cross-functional Team Leadership.

Advisors

  • Dr. Colin P. Derdeyn, MD
    Unconfirmed
  • Dr. Bruce C.V. Campbell, MD
    Unconfirmed
    Dr. Jin-Moo Lee, MD, PhD
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free